MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 02-28-2026
Insulet Corporation Operating Income 2011-2026 | PODD
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Insulet Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 474 M | 309 M | 220 M | 37.6 M | 126 M | 51.5 M | 50 M | 27.4 M | -7.4 M | -10.7 M | -48.7 M | -8.87 M | -26.7 M | -36 M | -42.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 474 M | -48.7 M | 74.3 M |
Quarterly Operating Income Insulet Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118 M | 121 M | 88.8 M | - | 88.1 M | 54.5 M | 56.9 M | - | 54.8 M | 31.1 M | 27.7 M | - | 2.9 M | -26.7 M | 37.9 M | - | 33.7 M | 26.3 M | 16.3 M | - | 23.8 M | 27.5 M | 7.5 M | - | 17 M | 7.6 M | 7.3 M | 16.2 M | 6.86 M | 4.32 M | - | -768 K | 2.05 M | -3.36 M | -5.31 M | -4.14 M | 2.42 M | -1.29 M | -7.7 M | -12.6 M | -14.8 M | -14.1 M | -7.27 M | - | -2.88 M | -5.28 M | -1.89 M | - | -17.3 M | -5.82 M | -6.21 M | - | -8.47 M | -10.5 M | -10.9 M | - | -9.77 M | -14.9 M | -7.27 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 121 M | -26.7 M | 14.2 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 12.37 | -4.85 % | $ 1.86 B | USA |
 |
Aziyo Biologics
AZYO
|
-30.5 M | - | 1.37 % | $ 20.5 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 24.26 | -0.12 % | $ 205 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 38.61 | 0.29 % | $ 5.75 K | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.59 | 0.32 % | $ 122 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 8.29 | 1.22 % | $ 595 M |  Israel |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 9.7 | 0.31 % | $ 1.31 B | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 41.54 | -3.37 % | $ 1.29 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 4.19 | -1.41 % | $ 156 M |  France |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
-7.85 M | $ 29.14 | -0.27 % | $ 1.34 B | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.26 | -1.21 % | $ 113 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Pulmonx Corporation
LUNG
|
-57.7 M | $ 1.59 | 10.07 % | $ 62.2 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.51 | -2.68 % | $ 52.4 M | USA |
 |
Medtronic PLC
MDT
|
5.96 B | $ 92.77 | -2.97 % | $ 119 B | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
-16.8 M | $ 0.81 | 1.92 % | $ 44.1 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 174.88 | -4.0 % | $ 13.1 B | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 3.69 | -8.56 % | $ 781 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
8.05 B | $ 110.83 | -2.01 % | $ 193 B | USA |
 |
InMode Ltd.
INMD
|
85.4 M | $ 13.48 | -0.57 % | $ 871 M | Israel |
 |
Orthofix Medical
OFIX
|
-81.4 M | $ 12.56 | -2.41 % | $ 497 M |  Curacao |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
3.61 B | $ 72.16 | -0.07 % | $ 107 B | USA |
 |
IRadimed Corporation
IRMD
|
22 M | $ 99.47 | -5.37 % | $ 1.26 B | USA |
 |
Profound Medical Corp.
PROF
|
-30.3 M | - | - | $ 180 M | Canada |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.4 | -0.71 % | $ 22.6 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 17.63 | -4.6 % | $ 414 M | USA |